SNMMI calls for clarity over Leqembi PET scans
The Society of Nuclear Medicine and Molecular Imagine (SNMMI) has called for clarity over whether amyloid PET scans will be covered for potential candidates for the new Alzheimer’s disease drug Leqembi (lecanemab).